The ClearBridge Global Value Improvers Strategy invests in equity securities of global companies that are considered to be undervalued, and are improving on environmental, social and governance measures through transforming their own products and services or enabling other entities to advance ESG objectives.
In this video, Portfolio Manager, Grace Su is joined by Head of APAC Business Development, Matt Bushby to delve into the investment philosophy supporting this Strategy and explore what the Strategy aims to achieve.
Drug development appears to be stabilizing, as improving biopharma funding and healthier demand create a more constructive backdrop for contract research organizations and life science tools companies.
Read full article